Angiogenic growth factors and/or cellular therapy for myocardial regeneration: a comparative study
- PMID: 15282461
- DOI: 10.1016/j.jtcvs.2004.04.007
Angiogenic growth factors and/or cellular therapy for myocardial regeneration: a comparative study
Abstract
Background: Locally delivered angiogenic growth factors and cell implantation have been proposed for patients with myocardial infarcts without a possibility of percutaneous or surgical revascularization. The goal of this study was to compare the effects of these techniques in an experimental model of myocardial infarct.
Methods: Left ventricular myocardial infarction was created in 27 sheep by ligation of 2 coronary arteries. Three weeks after creation of the infarct, animals were randomized into 4 groups. In group 1, sheep received a culture medium injection to the infarct area (control group); group 2 underwent autologous myoblast implantation; group 3 received vascular endothelial growth factor; and group 4 received injection of both vascular endothelial growth factor and myoblasts. Evaluation included serum troponin IC levels, echocardiography (2-dimensional and color kinesis), and immunohistologic studies for quantitative analysis of capillaries (3 months after surgery).
Results: Four animals died of refractory ventricular fibrillation during myocardial infarction; 2 died after surgery because of stroke and 2 because of infections. Serum troponin increased to 45.6 +/- 4.7 ng/mL at postinfarction day 2. Echocardiography at 3 months showed a significant limitation of left ventricular dilation in the cell group (57 +/- 11.1 mL) and in the cell plus vascular endothelial growth factor group (58.6 +/- 6.6 mL: control group, 74.4 +/- 11.2 mL; vascular endothelial growth factor group, 68.1 +/- 3.4 mL). Color kinesis echography showed important improvements of regional fractional area change in the cell group (from 13.6% +/- 0.8% to 21.1% +/- 1.5%) and in the cell plus vascular endothelial growth factor group (from 12.8% +/- 0.9% to 18.7% +/- 2.3%). The number of capillaries increased in the peri-infarct region of the vascular endothelial growth factor group (1036 +/- 75: control group, 785 +/- 31; cell group, 830 +/- 75; cell plus vascular endothelial growth factor group, 831 +/- 83).
Conclusions: In the cell therapy groups, regional ventricular contractility improved and heart dilatation was limited compared with either vascular endothelial growth factor or control; thus, postischemic remodeling was reduced. Angiogenesis was demonstrated in the vascular endothelial growth factor group, without improvement of ventricular function and remodeling. To improve local conditions for cell survival, further studies are warranted on prevascularization of myocardial scars with angiogenic therapy.
Comment in
-
Vascular endothelial growth factor before cells.J Thorac Cardiovasc Surg. 2005 Mar;129(3):696. doi: 10.1016/j.jtcvs.2004.11.018. J Thorac Cardiovasc Surg. 2005. PMID: 15746767 No abstract available.
Similar articles
-
Combined autologous cellular cardiomyoplasty with skeletal myoblasts and bone marrow cells in canine hearts for ischemic cardiomyopathy.J Thorac Cardiovasc Surg. 2005 Sep;130(3):646-53. doi: 10.1016/j.jtcvs.2005.02.024. J Thorac Cardiovasc Surg. 2005. PMID: 16153908
-
Effects of transplanted myoblasts transfected with human growth hormone gene on improvement of ventricular function of rats.Chin Med J (Engl). 2008 Feb 20;121(4):347-54. Chin Med J (Engl). 2008. PMID: 18304469
-
Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction.Ann Thorac Surg. 2005 Jul;80(1):229-36; discussion 236-7. doi: 10.1016/j.athoracsur.2005.02.072. Ann Thorac Surg. 2005. PMID: 15975372
-
Improving regenerating potential of the heart after myocardial infarction: factor-based approach.Life Sci. 2010 Mar 27;86(13-14):461-72. doi: 10.1016/j.lfs.2010.01.004. Epub 2010 Jan 20. Life Sci. 2010. PMID: 20093126 Review.
-
[Therapeutic angiogenesis and myocardial regenerative medicine for ischemic heart disease].Nihon Geka Gakkai Zasshi. 2006 Jan;107(1):33-7. Nihon Geka Gakkai Zasshi. 2006. PMID: 16482894 Review. Japanese.
Cited by
-
Echocardiographic evaluation of the effects of stem cell therapy on perfusion and function in ischemic cardiomyopathy.J Am Soc Echocardiogr. 2014 Feb;27(2):192-9. doi: 10.1016/j.echo.2013.10.011. Epub 2013 Dec 4. J Am Soc Echocardiogr. 2014. PMID: 24315764 Free PMC article.
-
Stem cell therapy: pieces of the puzzle.J Cardiovasc Transl Res. 2010 Feb;3(1):49-60. doi: 10.1007/s12265-009-9148-z. Epub 2009 Nov 19. J Cardiovasc Transl Res. 2010. PMID: 20119487 Free PMC article. Review.
-
Development of bioartificial myocardium using stem cells and nanobiotechnology templates.Cardiol Res Pract. 2010 Dec 29;2011:806795. doi: 10.4061/2011/806795. Cardiol Res Pract. 2010. PMID: 21253535 Free PMC article.
-
Stem Cells: The Game Changers of Human Cardiac Disease Modelling and Regenerative Medicine.Int J Mol Sci. 2019 Nov 16;20(22):5760. doi: 10.3390/ijms20225760. Int J Mol Sci. 2019. PMID: 31744081 Free PMC article. Review.
-
Genesis of myocardial repair with cardiac progenitor cells and tissue engineering.Heart Asia. 2010 Sep 18;2(1):109-11. doi: 10.1136/ha.2009.001651. eCollection 2010. Heart Asia. 2010. PMID: 27325955 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical